Kailera is developing a multi-modal obesity treatment franchise with exclusive global rights to Hengrui Pharma's obesity drug portfolio. The company holds over $1.3 billion in cash post-IPO, funding operations through mid-2028 and supporting key Phase 3 trial results for ribupatide and promising Phase 2/3 oral GLP-1 candidates. This diversified approach targets a growing obesity market with potential for differentiated efficacy and convenience. Despite competition and risks, the outlook remains bullish due to strong pipeline catalysts and financial stability.
Stella-Jones Inc. will hold a conference call on August 6, 2026, at 10:00 AM EST to discuss its second quarter financial results for 2026. The call will be accessible via webcast and phone, with a recording available afterward. Stella-Jones is a majo...
InStride's Capability Accelerators program won the "Best Professional Development Solution of the Year" at the 8th EdTech Breakthrough Awards. The program offers cohort-based, role-specific training designed to close skill gaps aligned with business ...
Stella-Jones Inc. announced a teleconference on August 6, 2026, at 10:00 AM EST to discuss its second quarter 2026 financial results. The call is open to investors, analysts, and interested parties, with live webcasting and phone access provided. A r...
Investec Bank plc, acting as advisor and joint broker to Advanced Medical Solutions Group Plc, disclosed public dealings in the company's ordinary shares on July 8, 2026. The bank purchased 1,490,908 shares at prices between 278 and 279.1, and sold 1...
Investec Bank plc, acting as joint broker to Gamma Communications Plc, disclosed public dealings in Gamma Communications shares on July 8, 2026. The bank purchased 176,904 ordinary shares at prices ranging from 806.5 to 886.5 pence and sold 159,904 s...
